More tools:Markets·Screener·Research·Chat

Kazia Therapeutics Limited American Depositary Shares (KZIA) Financial Statements

Kazia Therapeutics Limited American Depositary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SCPMJ4
XNAS · usd
12.01▼ 0.30 (-2.44%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close12.31
Day's Range11.95 – 12.47
52-Week Range4.86 – 17.40
Volume158.7K
Avg Volume263.1K
Share Statistics
Shares Outstanding
Employees6
ExchangeXNAS
Listed1999-01-06
Share count as of June 30, 2025
Loading Income Statement…
Key questions about Kazia Therapeutics Limited American Depositary Shares (KZIA)
What is Kazia Therapeutics Limited American Depositary Shares's Market Cap?
Kazia Therapeutics Limited American Depositary Shares's Market Cap is $9.7B, based on as-reported figures from SEC (XBRL) filings.
What is Kazia Therapeutics Limited American Depositary Shares's Enterprise Value?
Kazia Therapeutics Limited American Depositary Shares's Enterprise Value is $9.7B, based on as-reported figures from SEC (XBRL) filings.
What is Kazia Therapeutics Limited American Depositary Shares's Price / Sales?
Kazia Therapeutics Limited American Depositary Shares's Price / Sales is 352130.3×, based on as-reported figures from SEC (XBRL) filings.
What is Kazia Therapeutics Limited American Depositary Shares's EV / Revenue?
Kazia Therapeutics Limited American Depositary Shares's EV / Revenue is 350454.7×, based on as-reported figures from SEC (XBRL) filings.
What is Kazia Therapeutics Limited American Depositary Shares's Revenue (TTM)?
Kazia Therapeutics Limited American Depositary Shares's Revenue (TTM) is $27.6K, based on as-reported figures from SEC (XBRL) filings.
What is Kazia Therapeutics Limited American Depositary Shares's Net Income (TTM)?
Kazia Therapeutics Limited American Depositary Shares's Net Income (TTM) is -$15.5M, based on as-reported figures from SEC (XBRL) filings.
What is Kazia Therapeutics Limited American Depositary Shares's Diluted EPS (TTM)?
Kazia Therapeutics Limited American Depositary Shares's Diluted EPS (TTM) is -0.02, based on as-reported figures from SEC (XBRL) filings.
What is Kazia Therapeutics Limited American Depositary Shares's Net Debt?
Kazia Therapeutics Limited American Depositary Shares's Net Debt is -$46.3M, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2025Jun 30, 2024Jun 30, 2023Jun 30, 2022Jun 30, 2021Jun 30, 2020Jun 30, 2019Jun 30, 2018
Revenue from continuing operations
Revenue
Other income
Finance income
Expenses
Research and development expense
General and administrative expense
Impairment of intangible assets
(Loss) gain on remeasurement of other financial liabilities
Gain on remeasurement of promissory note
Gain on remeasurement of contingent consideration
Loss before income tax benefit
Income tax benefit
Loss after income tax benefit
Items that may be reclassified subsequently to profit or loss
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax
Other comprehensive income (loss), net of tax
Total comprehensive income/(loss)
Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited
Basic earnings per share
Diluted earnings per share